Skip to Content
UW Health SMPH
American Family Children's Hospital
Natalie S. Callander, MD close
Natalie S. Callander, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Natalie S. Callander, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Callander joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander has completed residency at Bellevue Hospital in New York and a Hematology/Oncology fellowship at the University of California-San Diego.



UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Internal Medicine
Medical Oncology
Fellowship University of California, San Diego
Residency Bellevue Hospital, New York
Internship Bellevue Hospital, New York, NY
Medical School Tufts University School of Medicine, Boston, MA, 1985


Madison Magazine Top Docs 2014

UW Health Patient Experience Physician Champion Award 2014

Best Doctors® in America 2014

UW Health Patient Experience Physician Champion Award 2013

Best Doctors® in America 2013

Best Doctors® in America 2011

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.


Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Programs & Conditions


Her clinical and research interests include: inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma.

PubMed Articles
Shah N Callander N Ganguly S Gul Z Hamadani M Costa L Sengsayadeth S Abidi M Hari P Mohty M Chen YB Koreth J Landau H Lazarus H Leather H Majhail N Nath R Osman K Perales MA Schriber J Shaughnessy P Vesole D Vij R Wingard J Giralt S Savani B . Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015 Mar 10;
[PubMed ID: 25769794]
Kumar SK LaPlant B Chng WJ Zonder J Callander N Fonseca R Fruth B Roy V Erlichman C Stewart AK . Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8
[PubMed ID: 25395429]
Sharma M Zhang MJ Zhong X Abidi MH Akpek G Bacher U Callander NS Dispenzieri A Freytes CO Fung HC Gale RP Gasparetto C Gibson J Holmberg LA Kindwall-Keller TL Klumpp TR Krishnan AY Landau HJ Lazarus HM Lonial S Maiolino A Marks DI Mehta P Mikhael Med JR Nishihori T Olsson R Ramanathan M Roy V Savani BN Schouten HC Scott E Tay J To LB Vesole DH Vogl DT Hari P . Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803
[PubMed ID: 25046833]
Callander N Markovina S Eickhoff J Hutson P Campbell T Hematti P Go R Hegeman R Longo W Williams E Asimakopoulos F Miyamoto S . Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82
[PubMed ID: 25168296]
Hope C Ollar SJ Heninger E Hebron E Jensen JL Kim J Maroulakou I Miyamoto S Leith C Yang DT Callander N Hematti P Chesi M Bergsagel PL Asimakopoulos F . TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22;123(21):3305-15
[PubMed ID: 24723682]
Asimakopoulos F Kim J Denu RA Hope C Jensen JL Ollar SJ Hebron E Flanagan C Callander N Hematti P . Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Oct;54(10):2112-21
[PubMed ID: 23432691]
Hebron E Hope C Kim J Jensen JL Flanagan C Bhatia N Maroulakou I Mitsiades C Miyamoto S Callander N Hematti P Asimakopoulos F . MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar;160(6):779-84
[PubMed ID: 23252623]
Kim J Denu RA Dollar BA Escalante LE Kuether JP Callander NS Asimakopoulos F Hematti P . Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug;158(3):336-46
[PubMed ID: 22583117]
Young EW Pak C Kahl BS Yang DT Callander NS Miyamoto S Beebe DJ . Microscale functional cytomics for studying hematologic cancers. Blood. 2012 Mar 8;119(10):e76-85
[PubMed ID: 22262772]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS . VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Markovina S Callander NS O'Connor SL Xu G Shi Y Leith CP Kim K Trivedi P Kim J Hematti P Miyamoto S . Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010 Jul 6;9:176
[PubMed ID: 20604947]
Markovina S Callander NS O'Connor SL Kim J Werndli JE Raschko M Leith CP Kahl BS Kim K Miyamoto S . Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356-64
[PubMed ID: 18708367]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL . Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]